Solesence Names CFO; 60,000-Share Option Grant Disclosed

Rhea-AI Filing Summary

Solesence, Inc. reported an initial Form 3 disclosing that Laura C. Riffner became Chief Financial Officer and received an option to purchase 60,000 shares of common stock on 09/03/2025. The option vests in three equal annual installments beginning 09/03/2026 and expires on 09/03/2032, with a strike price set at the NASDAQ closing price on the grant date. The filing was signed on 10/06/2025 and notes delays due to CIK availability and EDGAR Next technical issues.

Positive

• Experienced CFO hire signaled by appointment of Laura C. Riffner
• Long-dated equity incentive (expiration 09/03/2032) aligns executive and shareholder interests

Negative

• Filing delay due to missing CIK and EDGAR Next technical issues
• Vesting conditional on continued employment, creating potential forfeiture risk if tenure is short

Insights

Corporate Governance Analyst

New CFO received a standard multi‑year option package aligning pay with tenure.

The grant of 60,000 options with a three‑year vesting schedule is a common structure to link executive compensation to continued service and potential share price appreciation. The strike price is tied to the NASDAQ closing price on 09/03/2025, which makes the award performance‑neutral at grant and valuable only if the share price rises.

Key dependencies include the company’s stock performance over the next 3 years and continued employment through each vesting date; the option expires on 09/03/2032. Investors can monitor dilution impact and any further grants in subsequent filings within the next 12–36 months.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Riffner Laura C

Role Chief Financial Officer

Type	Security	Shares	Price	Value
holding	Common Stock (right to purchase	--	--	--

Holdings After Transaction: Common Stock (right to purchase — 60,000 shares (Direct)

Footnotes (1)

1. [object Object]

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Riffner Laura C

(Last) (First) (Middle)

1319 MARQUETTE DRIVE

(Street)

ROMEOVILLE IL 60446

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/03/2025

3. Issuer Name and Ticker or Trading Symbol
SOLESENCE, INC. [ SLSN ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock (right to purchase	09/03/2026(1)	09/03/2032	Common Stock	60,000	$3.5	D

Explanation of Responses:

1. Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.

Remarks:

Ms. Riffner began employment with Solesence, Inc. on September 3, 2025. This option grant was effective that day, with the strike price based upon the closing NASDAQ market price that same day. We did not have Ms. Riffner's CIK number available to complete this filing timely, this was compounded by technical issues relating to the adoption of EDGAR Next.

	/s/ Laura C. Riffner	10/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 3 filed for Solesence (SLSN) disclose?

It discloses that Laura C. Riffner was appointed CFO and granted an option to buy 60,000 shares on 09/03/2025, vesting in three equal annual installments and expiring on 09/03/2032.

When do Ms. Riffner's options begin to vest?

Vesting begins on 09/03/2026 and occurs in three equal annual installments subject to certain restrictions.

What is the strike price for the option grant?

The strike price was set equal to the NASDAQ closing market price on 09/03/2025 (the filing states the price was based on that closing price).

Why was the Form 3 filed on 10/06/2025 rather than sooner?

The filing notes delays due to lacking Ms. Riffner's CIK number and technical issues related to adoption of EDGAR Next.

How long do the options remain exercisable?

The options expire on 09/03/2032.